ICON (ICLR) vs MaxCyte (MXCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
ICON (ICLR) has outperformed MaxCyte (MXCT) over the past year, losing 12.1% versus a loss of 32.9%. Over five years, ICLR leads with a -40.3% price change compared with -90.6% for MXCT. ICON is the larger company by market cap ($12.66 billion vs $107.3 million), about 117.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ICLR | MXCT |
|---|---|---|
| Share price | $164.08 | $1.04 |
| Market cap | $12.66B | $107.33M |
| 1-day change | +1.48% | -4.59% |
| YTD return | -9.95% | -32.90% |
| 1-year return | -12.09% | -32.90% |
| 5-year return | -40.34% | -90.57% |
| P/E ratio (TTM) | 172.72 | — |
| Forward P/E | 13.88 | — |
| EPS (TTM) | $0.95 | $-0.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $8.25B | — |
| Revenue growth (YoY) | +0.76% | — |
| Net income (latest FY) | $229.34M | — |
| Gross margin | 26.37% | — |
| Operating margin | 5.37% | — |
| Net margin | 2.78% | — |
| 52-week high | $203.91 | $1.87 |
| 52-week low | $66.57 | $0.643 |
| Distance from 52-week high | -19.53% | -44.24% |
| Analyst consensus | buy | — |
| Avg. price target upside | +12.39% | — |
| Average volume | 812.83K | 699.83K |
| Shares outstanding | 77.15M | 103.21M |
| Employees | 40,200 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ICON is about 117.9 times larger than MaxCyte by market value ($12.66B vs $107.33M).
- ICLR has outperformed MXCT by 20.8 percentage points over the past year.
About ICON
ICLR stock →ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 40,200 employees
ICLR vs MXCT FAQ
Which is bigger, ICON or MaxCyte?
ICON (ICLR) is larger, with a market capitalization of $12.66B compared with $107.33M for MaxCyte (MXCT).
Which stock has performed better over the past year, ICLR or MXCT?
ICLR returned -12.09% over the past 12 months, compared with -32.90% for MXCT (price return, excluding dividends). Past performance does not predict future results.
Are ICON and MaxCyte in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.